History of good clinical practice (GCP): a sourced timeline from Helsinki to E6(R3)

At a glance

• Good clinical practice became a single international standard when the ICH Steering Committee approved the E6 guideline at Step 4 on 1 May 1996 and recommended it for adoption to the three ICH regulatory bodies. The consultation draft had been released at Step 2 on 27 April 1995.
• E6 has had two substantive revisions: E6(R2), an integrated addendum adopted at Step 4 on 9 November 2016, and E6(R3), released for consultation on 19 May 2023 and adopted at Step 4 on 6 January 2025. E6(R1), dated 10 June 1996, was a set of editorial corrections.
• An ICH Step 4 date is not an effective date. According to the EMA, the E6(R3) principles and Annex 1 came into effect in the EU on 23 July 2025.
• E6(R3) and E8(R1) both say the ethical principles behind GCP have their origin in the Declaration of Helsinki.
• ICH E6 is a guideline. It gets legal force through regional law, such as Regulation (EU) No 536/2014, which requires sponsors and investigators to follow the principles of good clinical practice.

The history of good clinical practice (GCP) is usually told as a chain of scandals and codes with dates attached, and many of those dates differ from one page to the next. This timeline takes a stricter line. Every date below comes from the document that sets it, or from a regulator’s page we opened and name. Where the popular story includes an event we could not date from those sources, the event is either undated or left out, and the article says so.

The timeline, with sources

Date	Event	Source
1938	US Federal Food, Drug, and Cosmetic Act requires new drugs to be shown safe before marketing	FDA, Milestones in U.S. Food and Drug Law
1962	Kefauver-Harris Drug Amendments require proof of effectiveness before marketing, the same year thalidomide is found to have caused birth defects in western Europe	FDA, Milestones in U.S. Food and Drug Law
1979	Belmont Report published by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research	45 CFR 46.101, footnote
30 May 1980	Federal Register origin of FDA’s 21 CFR Part 50, Protection of Human Subjects	21 CFR Part 50 source note
27 January 1981	Federal Register origin of Part 50’s informed consent subpart and of 21 CFR Part 56 on IRBs	21 CFR Part 50 subpart B and Part 56 source notes
27 April 1995	ICH E6 approved at Step 2 and released for public consultation	ICH E6(R3) document history
1 May 1996	ICH E6 approved at Step 4 and recommended for adoption to the three ICH regulatory bodies	ICH E6(R3) document history
10 June 1996	E6(R1): post-Step 4 editorial corrections	ICH E6(R3) document history
17 July 1997	The original ICH E8 guideline approved at Step 4	ICH E8(R1) document history
4 April 2001	Directive 2001/20/EC on implementing good clinical practice in clinical trials in the EU	Regulation (EU) No 536/2014, footnote 3
16 April 2014	Regulation (EU) No 536/2014 signed in Strasbourg	Regulation (EU) No 536/2014, Article 99
9 November 2016	E6(R2) integrated addendum adopted at Step 4	ICH E6(R3) document history
6 October 2021	E8(R1) adopted at Step 4	ICH E8(R1) document history
31 January 2022	Regulation 536/2014 enters into application and repeals Directive 2001/20/EC	EMA, Clinical Trials Regulation page
19 May 2023	E6(R3) endorsed at Step 2 and released for public consultation	ICH E6(R3) document history
6 January 2025	E6(R3) adopted at Step 4	ICH E6(R3) document history
23 July 2025	E6(R3) principles and Annex 1 come into effect in the EU	EMA, ICH E6 guideline page
3 June 2026	E6(R3) Annex 2 reaches Step 4, due to come into effect in the EU on 15 January 2027	EMA, ICH E6 guideline page

Before GCP was a guideline: the ethical and legal roots

The Declaration of Helsinki

ICH E6(R3) describes GCP as an international ethical, scientific and quality standard, and says trials conducted under it help assure that conduct is consistent with “the principles that have their origin in the Declaration of Helsinki”. Principle 1 repeats the point, and Annex 1 §2.8.1 asks investigators obtaining consent to adhere to those same ethical principles. ICH E8(R1) §2.1 says the principles of ethical conduct and participant protection have their origins in the Declaration of Helsinki and should be observed in all human clinical investigations. The 2016 E6(R2) text on ich.org opened with the same reference.

The declaration is the one ethical source the GCP guidelines name. None of the regulatory texts or regulator pages we opened gives the year it was adopted, so the timeline leaves it undated rather than repeat a year from secondary pages.

US drug law and human subject protection

FDA’s own milestones page dates two laws that shaped clinical research in the US. The 1938 Federal Food, Drug, and Cosmetic Act required new drugs to be shown safe before marketing. In 1962, the year thalidomide was found to have caused birth defects in thousands of babies in western Europe, the Kefauver-Harris Drug Amendments required manufacturers, for the first time, to prove a product’s effectiveness to FDA before marketing it.

The ethics framework came later. 45 CFR 46, the HHS policy for protecting human research subjects, says agency heads must exercise their judgment on what the policy covers consistently with the ethical principles of the Belmont Report (§46.101(c)), and any waiver must use procedures consistent with those principles (§46.101(i)). A footnote to §46.101 dates the Belmont Report to 1979 and names its author, the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. FDA’s milestones page records that in 1981 FDA and HHS revised their human subject protection regulations based on the Belmont Report.

FDA’s rules match that chronology. The source notes in the CFR show 21 CFR Part 50 originating in a Federal Register notice of 30 May 1980 (45 FR 36390), and both Part 50’s informed consent subpart and Part 56 on institutional review boards originating on 27 January 1981 (46 FR 8951 and 46 FR 8975). Those notes show where the current text began, and later amendments are listed after them.

Events this page does not date

The Nuremberg Code is often placed at the start of this story. None of the GCP guidelines or regulations in our sources refers to it, and we did not open a primary source that dates it, so it stays out of the timeline. The same applies to the year ICH was founded: ICH’s history page did not render when we checked, and the guideline texts do not state it.

Why harmonise: from national rules to one ICH standard

Before ICH E6, regions wrote their own good clinical practices. The introduction to the E6(R2) guideline on ich.org says the objective was a unified standard for the European Union, Japan and the United States so that their regulators could accept each other’s clinical data, and that it was developed with consideration of the good clinical practices of those three regions and of Australia, Canada, the Nordic countries and the World Health Organization.

E6(R3) keeps the aim and widens the circle. Its introduction states that the objective is a unified standard that helps regulators in ICH member countries and regions accept each other’s clinical trial data.

Who wrote it: the E6(R3) title page says the guideline was developed by the relevant ICH Expert Working Group and went through consultation by the regulatory parties under the ICH process. The approving body changed over time. The 1995 and 1996 entries in the document history record approval by the ICH Steering Committee, while the 2016, 2023 and 2025 entries record endorsement or adoption by members of the ICH Assembly.

ICH E6 (1995 to 1996): the first consolidated GCP guideline

The E6(R3) document history gives the sequence. The Steering Committee approved E6 under Step 2 and released it for public consultation on 27 April 1995. It approved the final text under Step 4 on 1 May 1996 and recommended it for adoption to the three ICH regulatory bodies. On 10 June 1996 it approved post-Step 4 editorial corrections, and that corrected text carries the code E6(R1).

So “when was GCP introduced” has two honest answers. National good clinical practices existed before ICH, as the E6(R2) introduction acknowledges. GCP as one ICH standard dates from Step 4 on 1 May 1996. A companion guideline followed: the E8(R1) document history shows the original ICH E8 approved under Step 4 on 17 July 1997.

E6(R2) (2016): the integrated addendum and risk-based thinking

According to the E6(R3) document history, the Regulatory Members of the ICH Assembly adopted E6(R2) under Step 4 on 9 November 2016 as an integrated addendum to E6(R1). The changes went directly into named sections of the existing guideline, including the introduction, the glossary, and a run of sponsor sections from 5.0 to 5.0.7.

The addendum explains itself. Its text on ich.org says the scale, complexity and cost of trials had grown since the guideline was written, that E6(R1) had been prepared when trials were largely paper-based, and that centralised monitoring could now benefit a broader range of trials. The guideline was amended to encourage more efficient approaches to trial design, conduct, oversight, recording and reporting, and its standards for electronic records and essential documents were updated. In E6(R2), the sponsor section opens with section 5.0, Quality Management, one of the sections the addendum changed.

E6(R3) (2023 to 2025): principles plus annexes

The members of the ICH Assembly endorsed E6(R3) under Step 2 and released it for consultation on 19 May 2023. The Regulatory Members adopted it under Step 4 on 6 January 2025.

R3 changes the shape of the document. Its introduction describes a guideline composed of principles and annexes, with the principles meant to apply across trial types and to stay relevant as technology and methods change. Annex 1 explains how the principles can be applied, and further annexes may be added. The introduction also says the guideline builds on ICH E8(R1), including designing quality into trials, identifying factors critical to quality and using a proportionate, risk-based approach. E8(R1) itself was adopted under Step 4 on 6 October 2021.

Adoption is not the end of the timeline. The EMA’s page for the guideline says the principles and Annex 1 came into effect in the EU on 23 July 2025, and that Annex 2 reached Step 4 with ICH adoption on 3 June 2026 and comes into effect in the EU on 15 January 2027. The E6(R3) text in our sources contains the principles and Annex 1 only. What R3 changed in practice is covered in ICH GCP after E6(R3), and how to work through the document in navigating the ICH E6(R3) guideline.

How GCP became binding: guideline versus law

ICH E6 is a guideline. Its title page describes the Step 4 text as recommended for adoption to the regulatory bodies of the ICH regions. Force comes from each region’s law.

In the EU, the first step was Directive 2001/20/EC of 4 April 2001, whose full title refers to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Regulation (EU) No 536/2014 records in recital 58 that the Directive introduced the concept of a sponsor, in line with international guidelines. Recital 79 explains the repeal of the Directive so that only one set of rules applies across the EU, and Article 96 repeals it from the date the Regulation applies. Article 99 set that date as six months after the Commission published a notice confirming that the EU portal and database were fully functional, and no earlier than 28 May 2016. According to the EMA, the Regulation entered into application on 31 January 2022, and trials approved under the Directive that were still running had to comply with the Regulation from 31 January 2025.

Article 47 of the Regulation is where GCP becomes a legal duty. It requires the sponsor and the investigator to ensure a trial is conducted in accordance with the protocol and with the principles of good clinical practice, and to take appropriate account of the ICH guidelines on good clinical practice. More on the Regulation is in EU Clinical Trial Regulation 536/2014.

In the US, the binding rules are regulations. 21 CFR Part 50 applies to all clinical investigations FDA regulates under sections 505(i) and 520(g) of the Federal Food, Drug, and Cosmetic Act and to investigations supporting applications for FDA-regulated products (§50.1). Part 56 sets the standards for the composition, operation and responsibility of IRBs that review FDA-regulated investigations (§56.101). 45 CFR 46 applies to human subjects research conducted, supported or otherwise subject to regulation by a federal department or agency that makes the policy applicable (§46.101(a)). The practical side of those rules is in informed consent in clinical trials and IRB approval decoded.

What the history explains about today’s GCP

GCP has carried two aims from the start. The E6(R2) introduction promised public assurance that the rights, safety and well-being of trial subjects are protected and that trial data are credible. E6(R3) says GCP helps assure that participants’ rights, safety and well-being are protected and that trial results are reliable. The wording moved from “subjects” to “participants” and from “credible” data to “reliable” results, and the pairing of participant protection with trustworthy results stayed.

The history also explains why R3 reads as principles rather than a procedure list. E6(R1) was written for paper-based trials and needed an addendum once electronic data and centralised monitoring arrived. R3’s introduction says its principles are meant to stay relevant as technology and methods change, and that the guideline is media neutral. The 11 principles themselves are covered in understanding the principles of GCP, the ethics behind them in the role of ethics in clinical trials and vulnerable populations in clinical research, the risk-based approach in RBQM under ICH E6(R3), and what staff must be trained on in GCP training requirements.

Common myths and dating errors

• “E6(R3) was released in 2023.” The 2023 date is the Step 2 consultation draft. ICH adopted the final text at Step 4 on 6 January 2025, and regional effective dates came later, such as 23 July 2025 in the EU.
• “E6(R1) was the first revision.” R1 was the editorial correction of the 1996 text on 10 June 1996. The first substantive revision was R2 in 2016.
• “GCP started in 1996.” ICH GCP did. National good clinical practices in the EU, Japan, the US and elsewhere existed before it, as the E6(R2) introduction notes.
• “ICH GCP is law.” It is a guideline recommended to regulators. In the EU, Article 47 of Regulation 536/2014 makes the principles of GCP a legal duty, and in the US the binding rules sit in regulations such as 21 CFR Parts 50 and 56.
• “Thalidomide led directly to ICH GCP.” FDA dates the thalidomide findings and the Kefauver-Harris Amendments to 1962, and both concern drug safety and effectiveness law. None of the sources we opened draws a direct line from them to the 1996 guideline.
• A single “release date” for any version. Each version has a consultation date, an adoption date and, in each region, an effective date. Name the one you mean.

Sources

• ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025, including its document history
• ICH E8(R1) General Considerations for Clinical Studies, adopted 6 October 2021, including its document history
• 45 CFR Part 46, Protection of Human Subjects (Common Rule)
• 21 CFR Part 50, Protection of Human Subjects, 2024 edition
• 21 CFR Part 56, Institutional Review Boards, 2024 edition
• Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use
• ICH E6(R2) Integrated Addendum to ICH E6(R1), Step 4 version dated 9 November 2016 (superseded, consulted for history)
• FDA, Milestones in U.S. Food and Drug Law
• EMA, Clinical Trials Regulation
• EMA, ICH E6 Good clinical practice scientific guideline